🕒 Last update: loading…

Stock Haoxi Health Technology Limited HAO

Haoxi Health Technology Limited — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ❌ Price trend failed
  • ✅ Growth passed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2024 → 2025: 613.33%

Price change 2025 → 2026: -99.90%

Price change 2026 (year to date): -99.90%

Financial growth

Revenue CAGR (5 years): 26.41%

Earnings CAGR (5 years): 88.96%

Growth status: positive trend (>1%/yr) in revenue and earnings.

Debt

Debt-to-equity ratio: 0.11

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -0.01

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 99.91% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Haoxi Health Technology Limited–0.12+33.7 %🔒
Digitalbox plc–0.00+1.7 %–
Inuvo, Inc.–0.40+3.8 %–
Nextedia S.A.7.80.15+11.8 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Haoxi Health Technology Limited over the latest fiscal years.

Revenue
54.8 m USD
fiscal year 2026
Net income
-9.5 m USD
fiscal year 2026
Net margin
-17.4 %
fiscal year 2026
Average annual growth
+33.7 %
Revenue growth over 5 years
Market cap
1.2 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202112.8 m304,0652.4 %n/a
202216.2 m244,5871.5 %+25.8 %
202328.2 m969,7523.4 %+74.7 %
202448.5 m1.3 m2.7 %+71.9 %
202532.8 m3.9 m11.8 %-32.4 %
202654.8 m-9.5 m-17.4 %+67.1 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Haoxi Health Technology Limited over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
1.78
risk zone (below 1.81)
Piotroski Score
4 / 9
4 to 6: average accounts
Net Debt / EBITDA
1.11 x
moderate debt
Fiscal year20222023202420252026
Cash and investments293,5111.2 m6.7 m8.6 m10.9 m
Total Debt505,399850,0601.2 m2.0 m1.6 m
Net Debt211,888-353,143-5.5 m-6.6 m-9.3 m
Equity-1.5 m1.6 m11.3 m17.4 m17.9 m
Total assets542,9934.5 m15.5 m21.6 m21.6 m
Operating cash flow-675,361-872,132-747,576-3.4 m-2.6 m
Investments (capex)8,69845,50055,3672.1 m3
Free cash-flow-684,059-917,632-802,943-3.4 m-2.6 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.01 x
Return on Equity (ROE)-56.4 %
Return on Invested Capital (ROIC)-45.0 %
Net margin-17.4 %
Debt / equity0.09 x
Current ratio4.53 x
Interest coverage-326.22 x
Free cash-flow yield-239.7 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Haoxi Health Technology Limited compared with its sector on the same exchange and with its main competitors.

Sector median P/E
18.1
communication services, Nasdaq
Sector over 10 years
34.2
10-year median, range 21.5 to 53.0

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Haoxi Health Technology Limited1.2 mn/a11.8 %
Harte Hanks, Inc. HHS29.9 mn/a-0.5 %
Scienjoy Holding Corporation SJ45.6 mn/a-47.3 %
Anghami Inc. ANGH30.5 mn/a-90.1 %
Dreamland Limited Class A Ordinary Shares TDIC352,394n/a14.0 %
Lottery.com Inc. SEGG4.0 mn/a-3,678.4 %
Everbright Digital Holding Limited Ordinary Shares EDHL11.3 mn/a-120.6 %
Alliance Entertainment Holding Corporation AENT252 m19.01.4 %
TNL Mediagene TNMG2.0 mn/a-99.0 %
Sector median (Nasdaq)18.1

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

Haoxi Health Technology Limited: dividend history, last distributions, stock splits and earnings releases.

Frequency
semi-annual
Last dividend
0.180 USD
ex-dividend on 12/02/2020
Yield
0.0 %
on the last known price
Years of increases
0
consecutive
Years of payments
0
uninterrupted
05.9811.9617.9423.922012 : 6.28 USD20122013 : 10.94 USD20132014 : 11.72 USD20142015 : 18.78 USD20152016 : 15.10 USD20162017 : 20.98 USD20172018 : 23.92 USD20182019 : 13.86 USD20192020 : 0.180 USD2020

Annual dividend per share (USD), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.

Latest ex-dividend dates

Ex-dividendAmountPayment
12/02/20200.180 USD26/02/2020
23/12/201913.86 USD31/12/2019
24/12/201823.92 USD31/12/2018
26/12/201720.98 USD29/12/2017
23/12/201615.10 USD30/12/2016
24/12/201518.78 USD31/12/2015
24/12/201411.72 USD31/12/2014
24/12/201310.94 USD31/12/2013

Stock splits

DateOperation
14/08/2026reverse split: 1 share for 20
21/05/2026reverse split: 1 share for 128
27/01/2025reverse split: 1 share for 25

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Haoxi Health Technology Limited.

Free float
100.0 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 26/01/2024
ISIN code
KYG4290F1000
Workforce
30
full-time employees
Chief executive
Zhen Fan

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Haoxi Health Technology Limited

What is the Haoxi Health Technology Limited share price?

Latest recorded price: 2.08 USD on 13/11/2026, for a market cap of 1.2 m USD.

What is the revenue of Haoxi Health Technology Limited?

54.8 m USD for fiscal year 2026, with net income of -9.5 m USD (net margin -17.4 %).

Does Haoxi Health Technology Limited pay a dividend?

Yes. Latest dividend: 0.180 USD per share, ex-dividend on 12/02/2020. Over 12 months: 0.0000 USD. Yield on the latest known price: 0.0 %.

Is Haoxi Health Technology Limited stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN KYG4290F1000).

How many employees does Haoxi Health Technology Limited have?

30 full-time employees according to the latest published profile.

Who runs Haoxi Health Technology Limited?

Zhen Fan is the company's chief executive.

07

Similar stocks